Comparative Risk of Angioedema With Sacubitril-Valsartan vs Renin-Angiotensin-Aldosterone Inhibitors
Authors:
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Comparative Risk for Angioedema Associated With the Use of Drugs That Target the Renin-Angiotensin-Aldosterone SystemArchives of internal medicine (1960), 2012
- Valsartan-Induced Angioedema in a Patient on Angiotensin-Converting Enzyme Inhibitor for YearsAmerican Journal of Therapeutics, 2012
- Design considerations, architecture, and use of the Mini‐Sentinel distributed data systemPharmacoepidemiology and Drug Safety, 2012
- A policy framework for public health uses of electronic health dataPharmacoepidemiology and Drug Safety, 2012
- The organizational structure and governing principles of the Food and Drug Administration's Mini‐Sentinel pilot programPharmacoepidemiology and Drug Safety, 2012
- A combined comorbidity score predicted mortality in elderly patients better than existing scoresJournal of Clinical Epidemiology, 2011
- Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity‐score matched samplesStatistics in Medicine, 2009
- Influenza Vaccination and Mortality: Differentiating Vaccine Effects From BiasAmerican Journal of Epidemiology, 2009
- Angioedema Incidence in US Veterans Initiating Angiotensin-Converting Enzyme InhibitorsHypertension, 2008
- Losartan Increases Bradykinin Levels in Hypertensive HumansCirculation, 2005